Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience

Abstract Introduction In November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild‐to‐moderate COVID‐19 at high risk for disease progression. Methods We retrospectively reviewed 38 adult hematology patients who received mAbs from 1...

Descripción completa

Detalles Bibliográficos

Autores principales:	Idoroenyi Amanam, Janny Yao, Alfredo Puing, Ni‐Chun Tsai, Diana Samuels, Dat Ngo, Stephanie Ho, Haris Ali, Ahmed Aribi, Shukaib Arslan, Andrew Artz, Myo Htut, Paul Koller, Amandeep Salhotra, Karamjeet Sandhu, Liana Nikolaenko, Anna Pawlowska, Geoffrey Shouse, Anthony Stein, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Sanjeet Dadwal, Monzr M. Al Malki
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2023-05-01
Colección:	Cancer Medicine
Materias:	cancer stem cells hematologic malignancies leukemia target therapy viral infection
Acceso en línea:	https://doi.org/10.1002/cam4.5832
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!